Answers are grounded in this paper and cite their sources.
Background: Axial spondyloarthritis (AxSpA) severely affects quality of life, underscoring the need for effective treatments. Tofacitinib, recently approved in India for active ankylosing spondylitis, a subset of AxSpA, has shown significant efficacy and a favourable safety profile. However, real-world data in Indian AxSpA patients remain limited. This retrospective study evaluated the effectiveness and safety of tofacitinib in Indian AxSpA patients in a real-world setting. Methods: This single-centre, retrospective study at the Indian Spinal Injuries Centre (Delhi) reviewed records of 100 active AxSpA patients treated with generic tofacitinib 5 mg twice daily (BID) for 24 weeks. AxSpA was classified according to the Assessment of Spondyloarthritis International Society classification criteria. Efficacy was evaluated based on change in Ankylosing Spondylitis Disease Activity Score C-Reactive Protein (ASDAS-CRP) at 24 weeks. Safety was evaluated based on reported adverse events (AEs). Results: A total of 100 patients with active AxSpA were treated with tofacitinib 5 mg BID for 24 weeks (23 received tofacitinib monotherapy and 77 received tofacitinib plus on-demand nonsteroidal anti-inflammatory drugs [NSAIDs]). 88 were biologic-naïve, and 12 patients had previously received biologic therapy. At week 24, ASDAS-CRP significantly decreased from 2.94 ± 0.8 to 1.18 ± 0.58 (mean difference 1.76; 95% CI: 1.56-1.96; P < .001). CRP levels declined from 13.85 ± 9.6 to 4.69 ± 3.2 (mean difference 9.16; 95% CI: 7.23-11.09; P < .001). Inactive disease (ASDAS-CRP < 1.3) was achieved in 71% of patients. Tofacitinib was well tolerated with a low incidence of AEs. Conclusion: This retrospective real-world study supports the efficacy and safety of generic tofacitinib and its role as an NSAID-sparing agent in Indian patients with active AxSpA.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: